Oklahoma Code § 63-5030.4

Title 63. Public Health And Safety: Drug utilization review program
Open in Lexace · Ask the AI about this section
1.  The Medicaid Drug Utilization Review Board shall develop and
recommend to the Oklahoma Health Care Authority Board a

retrospective and prospective drug utilization review program for
medical outpatient drugs to ensure that prescriptions are
appropriate, medically necessary, and not likely to result in
adverse medical outcomes.
2.  The retrospective and prospective drug utilization review
program shall be operated under guidelines established by the
Medicaid Drug Utilization Review Board as follows:
a. The retrospective drug utilization review program
shall be based on guidelines established by the
Medicaid Drug Utilization Review Board using the
mechanized drug claims processing and information
retrieval system to analyze claims data in order to:
(1) identify patterns of fraud, abuse, gross overuse
or underuse, and inappropriate or medically
unnecessary care,
(2) assess data on drug use against explicit
predetermined standards that are based on the
compendia and other sources for the purpose of
monitoring:
(a) therapeutic appropriateness,
(b) overutilization or underutilization,
(c) appropriate use of generic drugs,
(d) therapeutic duplication,
(e) drug-disease contraindications
(f) drug-drug interactions,
(g) incorrect drug dosage,
(h) duration of drug treatment, and
(i) clinical abuse or misuse, and
(3) introduce remedial strategies in order to improve
the quality of care and to conserve program funds
or personal expenditures.
b. (1) The prospective drug utilization review program
shall be based on guidelines established by the
Medicaid Drug Utilization Review Board and shall
provide that, before a prescription is filled or
delivered, a review will be conducted by the
pharmacist at the point of sale to screen for
potential drug therapy problems resulting from:
(a) therapeutic duplication,
(b) drug-drug interactions,
(c) incorrect drug dosage or duration of drug
treatment,
(d) drug-allergy interactions, and
(e) clinical abuse or misuse.
(2) In conducting the prospective drug utilization
review, a pharmacist may not alter the prescribed

outpatient drug therapy without the consent of
the prescribing physician or purchaser.

‹ Prev All Oklahoma sections Next ›


Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.